ArticleNature communications2025
IKAROS levels are associated with antigen escape in CD19- and CD22-targeted therapies for B-cell malignancies.
Abstract read
In one paragraph
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- RHOA Deletion Downregulates CD19 and Promotes Dysfunctional Immune Microenvironments in CAR-T Resistant Large B-cell Lymphomas.Blood cancer discovery · 2026Article
- Plasticity under pressure: biology and detection of lineage switch in acute leukemia.Leukemia · 2026Review
- A genomic and epigenomic lens into the biology of acute lymphoblastic leukaemia.Nature reviews. Cancer · 2026Review
- mTORC1 inhibition upregulates CD20 and enhances anti-CD20 antibody efficacy in B-cell precursor acute lymphoblastic leukemia.Leukemia · 2026Article
- CellFuse Enables Multimodal Integration of Single-Cell and Spatial Proteomics Data for Systems-Level Analysis in Cancer.Cancer research · 2026Article
- Differential cytokine architecture in patients treated with CART19 versus CART22.Journal for immunotherapy of cancer · 2026Article
- Article
- CD19-negative relapse after CAR-T cell therapy: mechanisms of antigen escape and lineage switch.Frontiers in immunology · 2026Review
- From monoclonals to bispecific T cell engagers: the evolving antibody-based therapy landscape in acute myeloid leukemia.Frontiers in immunology · 2026Review
- Mechanistic basis and therapeutic modulation of T cell fitness to enhance CAR-T cell efficacy in hematological malignancies.Frontiers in immunology · 2026Review
- Affinity-matured CD72-targeting nanobody CAR T cells enhance elimination of antigen-low B-cell malignancies.Journal for immunotherapy of cancer · 2025Article
- Revisiting novel genomic classifiers in the era of immunotherapy for pediatric B-ALL.Hematology. American Society of Hematology. Education Program · 2025Review
- Mechanisms of Resistance to Novel Immunotherapies in B-Cell Lymphomas: Focus on CAR T and Bispecific Antibodies.Cancers · 2025Review
- Moving cellular therapies to the front line for PhCell reports. Medicine · 2025Article
- IKAROS levels are associated with antigen escape in CD19- and CD22-targeted therapies for B-cell malignancies.Nature communications · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Pablo DomiziDepartment of Pediatrics, Hematology, Oncology, Stem Cell Transplant and Regenerative Medicine, Stanford University, Stanford, CA, USA. domizi@stanford.edu.ORCID http://orcid.org/0000-0003-2903-0337
Jolanda SarnoDepartment of Pediatrics, Hematology, Oncology, Stem Cell Transplant and Regenerative Medicine, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0003-3488-0248
Astraea JagerDepartment of Pediatrics, Hematology, Oncology, Stem Cell Transplant and Regenerative Medicine, Stanford University, Stanford, CA, USA.
Milton MerchantDepartment of Pediatrics, Hematology, Oncology, Stem Cell Transplant and Regenerative Medicine, Stanford University, Stanford, CA, USA.
Kaithlen Zen B PachecoCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
Sean A Yamada-HunterCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-4372-6587
Maria Caterina RotirotiDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Yuxuan LiuDepartment of Pediatrics, Hematology, Oncology, Stem Cell Transplant and Regenerative Medicine, Stanford University, Stanford, CA, USA.
Reema BaskarDepartment of Pathology, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-3872-0164
Warren D ReynoldsCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
Brian J SworderDivision of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Bita SahafCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
Sean C BendallDepartment of Pathology, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0003-1341-2453
Charles G MullighanDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID http://orcid.org/0000-0002-1871-1850
Ash A AlizadehDivision of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-5153-5625
Allison B LeahyDivision of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Regina M MyersDivision of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Bonnie YatesPediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Hao-Wei WangLaboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-5408-9253
Nirali N ShahPediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-8474-9080
Robbie G MajznerDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0001-6969-8011
Crystal L MackallCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.ORCID http://orcid.org/0000-0001-6323-4304
Stephan A GruppDivision of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0001-8030-7595
David M BarrettKite Pharma, Santa Monica, CA, USA.
Elena SotilloCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-3993-1932
Kara L DavisDepartment of Pediatrics, Hematology, Oncology, Stem Cell Transplant and Regenerative Medicine, Stanford University, Stanford, CA, USA. kardavis@stanford.edu.ORCID http://orcid.org/0000-0002-7182-2592
Funding
Understanding and Overcoming Resistance to Immunotherapies in Childhood CancersU54CA232568 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI MACKALL, CRYSTAL, MARIS, JOHN M · 2018 to 2022
$13.1MImmunotherapeutic approaches to treat pediatric hematologic malignanciesZIABC011823 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI SHAH, NIRALI · 2019 to 2025
$6.1MPredicting Relapse at the Time of Diagnosis in Acute Lymphoblastic LeukemiaR01CA251858 · NCI · STANFORD UNIVERSITY · PI DAVIS, KARA LYNN · 2021 to 2025
$3.1MNext Generation Immunotherapies for Pediatric CancersR35CA283888 · NCI · STANFORD UNIVERSITY · PI Crystal Mackall · 2024 to 2026
$2.8MIntramural NIH HHS ZIA BC011823NCI NIH HHS R01 CA251858NCI NIH HHS R35 CA283888NCI NIH HHS U54 CA232568U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01-CA251858V Foundation for Cancer Research (V Foundation) Pediatric Immunotherapy Grant
Abstract
Antigen escape relapse is a major challenge in targeted immunotherapies, including CD19- and CD22-directed chimeric antigen receptor (CAR) T-cell for B-cell acute lymphoblastic leukemia (B-ALL). To identify tumor-intrinsic factors driving antigen loss, we perform single-cell analyses on 61 B-ALL patient samples treated with CAR T cells. Here we show that low levels of IKAROS in pro-B-like B-ALL cells before CAR T treatment correlate with antigen escape. IKAROS
Indexed as
Antigens, CD19Ikaros Transcription FactorPrecursor B-Cell Lymphoblastic Leukemia-LymphomaSialic Acid Binding Ig-like Lectin 2Tumor EscapeB-LymphocytesFemaleHumansImmunotherapy, AdoptiveMaleReceptors, Chimeric AntigenSingle-Cell AnalysisAntigens, CD19CD19 molecule, humanCD22 protein, humanIkaros Transcription FactorIKZF1 protein, humanReceptors, Chimeric AntigenSialic Acid Binding Ig-like Lectin 2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.